These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 35232215)

  • 21. Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies.
    Ballantyne CM; Bays HE; Philip S; Doyle RT; Braeckman RA; Stirtan WG; Soni PN; Juliano RA
    Atherosclerosis; 2016 Oct; 253():81-87. PubMed ID: 27596132
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Eicosapentaenoic acid, but not docosahexaenoic acid, increases mitochondrial fatty acid oxidation and upregulates 2,4-dienoyl-CoA reductase gene expression in rats.
    Willumsen N; Vaagenes H; Lie O; Rustan AC; Berge RK
    Lipids; 1996 Jun; 31(6):579-92. PubMed ID: 8784738
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Minimal food effect for eicosapentaenoic acid and docosahexaenoic acid bioavailability from omega-3-acid ethyl esters with an Advanced Lipid Technologies
    Lopez-Toledano MA; Thorsteinsson T; Daak AA; Maki KC; Johns C; Rabinowicz AL; Sancilio FD
    J Clin Lipidol; 2017; 11(2):394-405. PubMed ID: 28502496
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Short term effects of different omega-3 fatty acid formulation on lipid metabolism in mice fed high or low fat diet.
    Tang X; Li ZJ; Xu J; Xue Y; Li JZ; Wang JF; Yanagita T; Xue CH; Wang YM
    Lipids Health Dis; 2012 Jul; 11():70. PubMed ID: 22676394
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Icosapent ethyl: a review of its use in severe hypertriglyceridemia.
    Kim ES; McCormack PL
    Am J Cardiovasc Drugs; 2014 Dec; 14(6):471-8. PubMed ID: 25428605
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bioavailability of long chain omega-3 polyunsaturated fatty acids from phospholipid-rich herring roe oil in men and women with mildly elevated triacylglycerols.
    Cook CM; Hallaråker H; Sæbø PC; Innis SM; Kelley KM; Sanoshy KD; Berger A; Maki KC
    Prostaglandins Leukot Essent Fatty Acids; 2016 Aug; 111():17-24. PubMed ID: 27151222
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Novel ω-3 Acid Ethyl Ester Formulation Incorporating Advanced Lipid Technologies
    Lopez-Toledano MA; Thorsteinsson T; Daak A; Maki KC; Johns C; Rabinowicz AL; Sancilio FD
    Clin Ther; 2017 Mar; 39(3):581-591. PubMed ID: 28189364
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Different metabolism of EPA, DPA and DHA in humans: A double-blind cross-over study.
    Guo XF; Tong WF; Ruan Y; Sinclair AJ; Li D
    Prostaglandins Leukot Essent Fatty Acids; 2020 Jul; 158():102033. PubMed ID: 31740197
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diets enriched in menhaden fish oil, seal oil, or shark liver oil have distinct effects on the lipid and fatty-acid composition of guinea pig heart.
    Murphy MG; Wright V; Ackman RG; Horackova M
    Mol Cell Biochem; 1997 Dec; 177(1-2):257-69. PubMed ID: 9450671
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association.
    Skulas-Ray AC; Wilson PWF; Harris WS; Brinton EA; Kris-Etherton PM; Richter CK; Jacobson TA; Engler MB; Miller M; Robinson JG; Blum CB; Rodriguez-Leyva D; de Ferranti SD; Welty FK;
    Circulation; 2019 Sep; 140(12):e673-e691. PubMed ID: 31422671
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on plasma and red blood cell fatty acids in patients with very high triglyceride levels (results from the MARINE study).
    Braeckman RA; Manku MS; Bays HE; Stirtan WG; Soni PN
    Prostaglandins Leukot Essent Fatty Acids; 2013 Sep; 89(4):195-201. PubMed ID: 23992935
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Usefulness of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) in Women to Lower Triglyceride Levels (Results from the MARINE and ANCHOR Trials).
    Mosca L; Ballantyne CM; Bays HE; Guyton JR; Philip S; Doyle RT; Juliano RA
    Am J Cardiol; 2017 Feb; 119(3):397-403. PubMed ID: 27939227
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Update on the management of severe hypertriglyceridemia--focus on free fatty acid forms of omega-3.
    Pirillo A; Catapano AL
    Drug Des Devel Ther; 2015; 9():2129-37. PubMed ID: 25914523
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia.
    McKenney JM; Sica D
    Pharmacotherapy; 2007 May; 27(5):715-28. PubMed ID: 17461707
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Atherogenic Lipid/Lipoprotein, Apolipoprotein, and Inflammatory Parameters in Patients With Elevated High-Sensitivity C-Reactive Protein (from the ANCHOR Study).
    Miller M; Ballantyne CM; Bays HE; Granowitz C; Doyle RT; Juliano RA; Philip S
    Am J Cardiol; 2019 Sep; 124(5):696-701. PubMed ID: 31277790
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative effects of dietary n-3 docosapentaenoic acid (DPA), DHA and EPA on plasma lipid parameters, oxidative status and fatty acid tissue composition.
    Drouin G; Catheline D; Guillocheau E; Gueret P; Baudry C; Le Ruyet P; Rioux V; Legrand P
    J Nutr Biochem; 2019 Jan; 63():186-196. PubMed ID: 30412907
    [TBL] [Abstract][Full Text] [Related]  

  • 37. n-3 Docosapentaenoic Acid Intake and Relationship with Plasma Long-Chain n-3 Fatty Acid Concentrations in the United States: NHANES 2003-2014.
    Richter CK; Bisselou KS; Nordgren TM; Smith L; Appiah AK; Hein N; Anderson-Berry A; Kris-Etherton P; Hanson C; Skulas-Ray AC
    Lipids; 2019 Apr; 54(4):221-230. PubMed ID: 31025717
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial.
    Nicholls SJ; Lincoff AM; Garcia M; Bash D; Ballantyne CM; Barter PJ; Davidson MH; Kastelein JJP; Koenig W; McGuire DK; Mozaffarian D; Ridker PM; Ray KK; Katona BG; Himmelmann A; Loss LE; Rensfeldt M; Lundström T; Agrawal R; Menon V; Wolski K; Nissen SE
    JAMA; 2020 Dec; 324(22):2268-2280. PubMed ID: 33190147
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Update on marine omega-3 fatty acids: management of dyslipidemia and current omega-3 treatment options.
    Weintraub H
    Atherosclerosis; 2013 Oct; 230(2):381-9. PubMed ID: 24075771
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein B-containing lipoproteins in humans: a review.
    Oscarsson J; Hurt-Camejo E
    Lipids Health Dis; 2017 Aug; 16(1):149. PubMed ID: 28797250
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.